ChromaDex Reports Second Quarter Ingredient Sales Grew 155% Year-Over-Year and 52% Sequentially
date:Aug 13, 2014
itiation of separate clinical trials of both our NIAGEN nicotinamide riboside and PURENERGY caffeine alternative. Coupled with other active collaborations with numerous leading universities and research institutes studying the health benefits of NIAGEN, we anticipate results from these studies will be an incredible driver with respect to building consumer awareness for the ingredient. These studies will also be very important for validating the potential of NIAGEN as a pharmaceutical candidate
5/12 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/16 10:09